Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Where is the follicular lymphoma space moving?

Krish Patel • 3 Jun 2021
EHA 2021
Follicular Lymphoma Lymphoma Axicabtagene ciloleucel CAR-T Tazemetostat Umbralisib

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discussess the latest developments in the field of follicular lymphoma, highlighting the approval of the chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel, the EZH2 inhibitor tazemetostat, and the novel PI3K inhibitor umbralisib. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Krish Patel

1:01
The current landscape of antibody-based therapies in R/R DLBCL
Krish Patel • 11 Dec 2023
1:31
Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel • 11 Dec 2023
1:25
Hypertension prevalence in CLL and how it is affected by acalabrutinib treatment
Krish Patel • 11 Dec 2023
1:06
Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals